Alcorn Jane, McNamara Patrick J
Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0082, USA.
Antimicrob Agents Chemother. 2002 Jun;46(6):1831-6. doi: 10.1128/AAC.46.6.1831-1836.2002.
Treatment with antiviral agents that accumulate in breast milk may offer a novel approach to reduce the rates of vertical transmission of important viruses and the risk of clinical illness in suckling neonates. The present study evaluated the extent and mechanism of transfer of three antiviral nucleoside analogues into milk in a lactating rat model system. Acyclovir (0.26 mg/h), ganciclovir (0.13 mg/h), and zidovudine (0.5 mg/h) were each infused to steady-state concentrations in six rats 15 to 16 days postpartum. The observed ratios of the concentrations in milk to the concentrations in serum (observed milk-to-serum ratio), calculated from the ratio of the steady-state concentration in serum to the steady-state concentration in milk, determined the extent of drug transfer into milk. To identify the mechanism of transfer into milk, the observed milk-to-serum ratio was compared to a predicted milk-to-serum ratio estimated from an in vitro passive diffusion model of transfer of each drug into milk. High-pressure liquid chromatography methods determined milk and serum drug concentrations. Mean +/- standard deviation observed milk-to-serum ratios for acyclovir, ganciclovir, and zidovudine were 5.1 +/- 1.4, 1.6 +/- 0.33, and 1.0 +/- 0.29, respectively, compared with their corresponding predicted ratios of 1.1, 0.85, and 0.71. These results suggest that acyclovir accumulates in milk due to active transport mechanisms, while passive diffusion processes govern the transfer of both ganciclovir and zidovudine into milk. The presence of all three antiviral drugs in milk and the potential for active drug transfer into milk warrants further investigation of the accumulation of other antiviral drugs in milk and their therapeutic benefits in reducing the vertical transmission of viruses and clinical sequelae in the breast-feeding infant.
使用在母乳中蓄积的抗病毒药物进行治疗,可能为降低重要病毒的垂直传播率以及哺乳新生儿患临床疾病的风险提供一种新方法。本研究在泌乳大鼠模型系统中评估了三种抗病毒核苷类似物向乳汁转移的程度和机制。对6只产后15至16天的大鼠分别输注阿昔洛韦(0.26毫克/小时)、更昔洛韦(0.13毫克/小时)和齐多夫定(0.5毫克/小时),直至达到稳态浓度。根据血清稳态浓度与乳汁稳态浓度之比计算得出的乳汁浓度与血清浓度之比(实测乳汁与血清浓度比),确定了药物向乳汁转移的程度。为了确定向乳汁转移的机制,将实测乳汁与血清浓度比与根据每种药物向乳汁转移的体外被动扩散模型估算的预测乳汁与血清浓度比进行了比较。采用高压液相色谱法测定乳汁和血清中的药物浓度。阿昔洛韦、更昔洛韦和齐多夫定的平均实测乳汁与血清浓度比分别为5.1±1.4、1.6±0.33和1.0±0.29,而它们相应的预测比值分别为1.1、0.85和0.71。这些结果表明,阿昔洛韦因主动转运机制而在乳汁中蓄积,而被动扩散过程则控制着更昔洛韦和齐多夫定向乳汁的转移。乳汁中存在所有三种抗病毒药物以及药物主动向乳汁转移的可能性,值得进一步研究其他抗病毒药物在乳汁中的蓄积情况及其在降低母乳喂养婴儿病毒垂直传播和临床后遗症方面的治疗益处。